Theracryf (TCF)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 0.24p
   
  • Change Today:
      0.000p
  • 52 Week High: 1.22
  • 52 Week Low: 0.20
  • Currency: UK Pounds
  • Shares Issued: 2,148.96m
  • Volume: 1,740,479
  • Market Cap: £5.05m
  • Beta: 0.00

Evgen Pharma in talks about funding for Covid-19 clinical trial

By Michele Maatouk

Date: Friday 15 May 2020

LONDON (ShareCast) - (Sharecast News) - AIM-listed Evgen Pharma said on Friday that it is in talks with a potential source of funds that would help pay for a clinical trial in Covid-19 patients, in which it would provide support with its lead product, SFX-01.
The lead product from Evgen, which is a clinical stage drug development company focusing on the treatment of cancer and neurological conditions, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

The statement was made in response to a rise in the share price in recent days.

"A further announcement will be made if these discussions are successful," it said.

At 1305 BST, the shares were up 27% at 14.48p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Theracryf Market Data

Currency UK Pounds
Share Price 0.24p
Change Today 0.000p
% Change 0.00 %
52 Week High 1.22
52 Week Low 0.20
Volume 1,740,479
Shares Issued 2,148.96m
Market Cap £5.05m
Beta 0.00

Theracryf Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
44.27% below the market average44.27% below the market average44.27% below the market average44.27% below the market average44.27% below the market average
58.33% above the sector average58.33% above the sector average58.33% above the sector average58.33% above the sector average58.33% above the sector average
Price Trend
95.38% below the market average95.38% below the market average95.38% below the market average95.38% below the market average95.38% below the market average
87.5% below the sector average87.5% below the sector average87.5% below the sector average87.5% below the sector average87.5% below the sector average
Income Not Available
Growth
16.52% below the market average16.52% below the market average16.52% below the market average16.52% below the market average16.52% below the market average
31.25% below the sector average31.25% below the sector average31.25% below the sector average31.25% below the sector average31.25% below the sector average

Theracryf Dividends

No dividends found

Trades for 09-May-2025

Time Volume / Share Price
14:24 5,000 @ 0.23p
13:29 109,301 @ 0.23p
09:30 1,511,364 @ 0.26p
08:35 3,703 @ 0.27p
08:08 111,111 @ 0.26p

Theracryf Key Personnel

CEO Huw Jones
CFO Toni Hänninen

Top of Page